Bionomics Has Initiated Patient Screening For The Phase 3 AFFIRM-1 Trial Evaluating The Safety And Efficacy Of BNC210 For The Acute, As-needed Treatment Of Social Anxiety Disorder, Topline Results Are Expected In Q3 2025
Portfolio Pulse from Benzinga Newsdesk
Bionomics has started patient screening for its Phase 3 AFFIRM-1 trial to evaluate the safety and efficacy of BNC210 for treating social anxiety disorder. Topline results are expected in Q3 2025.

July 18, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bionomics has initiated patient screening for its Phase 3 AFFIRM-1 trial to evaluate BNC210 for social anxiety disorder, with results expected in Q3 2025.
The initiation of a Phase 3 trial is a significant milestone for Bionomics, indicating progress in their drug development pipeline. Positive results could lead to regulatory approval and commercialization, potentially boosting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100